Phase II Extension Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Phase of Trial: Phase I/II
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Rivogenlecleucel (Primary) ; Rimiducid
- Indications Haematological malignancies
- Focus Adverse reactions; Registrational
- Sponsors Bellicum Pharmaceuticals
- 01 Dec 2017 Planned number of patients changed from 120 to 175.
- 01 Dec 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 01 Dec 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History